- Home
- JLS vs ONCY Comparison
JLS vs ONCY Comparison
Compare JLS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | ONCY |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Investment Managers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.9M | 94.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JLS | ONCY |
|---|---|---|
| Price | $18.57 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 26.6K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.48 | $0.33 |
| 52 Week High | $17.97 | $1.51 |
Technical Indicators
Market Signals| Indicator | JLS | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 50.38 |
| Support Level | $18.67 | $0.79 |
| Resistance Level | $18.94 | $1.10 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.58 | 48.58 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.